scholarly journals Adolescents at Risk for MODY3 Diabetes Prefer Genetic Testing Before Adulthood

Diabetes Care ◽  
2007 ◽  
Vol 30 (6) ◽  
pp. 1571-1573 ◽  
Author(s):  
B. Liljestrom ◽  
T. Tuomi ◽  
B. Isomaa ◽  
L. Sarelin ◽  
K. Aktan-Collan ◽  
...  
Keyword(s):  
At Risk ◽  
2002 ◽  
Vol 6 (3) ◽  
pp. 203-205 ◽  
Author(s):  
Rachael Brandt ◽  
Ellen Hartmann ◽  
Zonera Ali ◽  
Rosemarie Tucci ◽  
Paul Gilman

2019 ◽  
Vol 7 (24) ◽  
pp. 4383-4388
Author(s):  
Dang Tien Truong ◽  
Ngo Van Nhat Minh ◽  
Dinh Phuong Nhung ◽  
Hoang Van Luong ◽  
Do Quyet ◽  
...  

BACKGROUND: β-thalassemia is one of the most common monogenic diseases worldwide. Preimplantation genetic testing (PGT) of β-thalassemia is performed to avoid affected pregnancies has become increasingly popular worldwide. In which, the indirect analysis using short tandem repeat (STRs) linking with HBB gene to detect different β-globin (HBB) gene mutation is a simple, accurate, economical and also provides additional control of contamination and allele-drop-out ADO. AIM: This study established microsatellite markers for PGT of Vietnamese β-thalassemia patient. METHODS: Fifteen (15) STRs gathered from 5 populations were identified by in silico tools within 1 Mb flanking the HBB gene. The multiplex PCR reaction was optimized and performed on 106 DNA samples from at-risk families. RESULTS: After estimating, PIC values were ≥ 0.7 for all markers, with expected heterozygosity and observed heterozygosity values ranged from 0.81 to 0.92 and 0.53 to 0.86, respectively. One hundred percent of individuals had at least seven heterozygous markers and were found to be heterozygous for at least two markers on either side of the HBB gene. The STRs panel was successfully performed on one at-risk family. CONCLUSION: In general, a pentadecaplex marker (all < 1 Mb from the HBB gene) assay was constituted for β-thalassemia PGT on Vietnamese population.


Heart ◽  
2020 ◽  
pp. heartjnl-2020-316798
Author(s):  
Monica Ahluwalia ◽  
Carolyn Y Ho

Genetic testing in hypertrophic cardiomyopathy (HCM) is a valuable tool to manage patients and their families. Genetic testing can help inform diagnosis and differentiate HCM from other disorders that also result in increased left ventricular wall thickness, thereby directly impacting treatment. Moreover, genetic testing can definitively identify at-risk relatives and focus family management. Pathogenic variants in sarcomere and sarcomere-related genes have been implicated in causing HCM, and targeted gene panel testing is recommended for patients once a clinical diagnosis has been established. If a pathogenic or likely pathogenic variant is identified in a patient with HCM, predictive genetic testing is recommended for their at-risk relatives to determine who is at risk and to guide longitudinal screening and risk stratification. However, there are important challenges and considerations to implementing genetic testing in clinical practice. Genetic testing results can have psychological and other implications for patients and their families, emphasising the importance of genetic counselling before and after genetic testing. Determining the clinical relevance of genetic testing results is also complex and requires expertise in understanding of human genetic variation and clinical manifestations of the disease. In this review, we discuss the genetics of HCM and how to integrate genetic testing in clinical practice.


2020 ◽  
Vol 159 ◽  
pp. 253
Author(s):  
R.M. Kahn ◽  
H. Krinsky ◽  
J. Chervenak ◽  
S.R. Anderson ◽  
K. Lipkin ◽  
...  

2002 ◽  
Vol 6 (4) ◽  
pp. 273-280 ◽  
Author(s):  
Hendrik Berth ◽  
Friedrich Balck ◽  
Andreas Dinkel

2018 ◽  
Vol 27 (6) ◽  
pp. 1428-1437 ◽  
Author(s):  
K. M. Stuttgen ◽  
J. M. Bollinger ◽  
R. L. Dvoskin ◽  
A. McCague ◽  
B. Shpritz ◽  
...  

2012 ◽  
Vol 127 (3) ◽  
pp. 544-551 ◽  
Author(s):  
Matthew B. Yurgelun ◽  
Rowena Mercado ◽  
Margery Rosenblatt ◽  
Monica Dandapani ◽  
Wendy Kohlmann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document